Simponi approved for non-radiographic axial spondyloarthritis

Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).
Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).

Further information
View Simponi drug record
Summary of Product Characteristics
Manufacturer: MSD

The licensed indications for Simponi (golimumab) have been extended to include the treatment of severe active non-radiographic axial spondyloarthritis with objective signs of inflammation in patients who are intolerant of, or unresponsive to, treatment with NSAIDs.

The recommended dose for the new indication is 50mg by sc inj monthly on the same date each month.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.